BridgeBio’s long-term limb-girdle muscular dystrophy data; QHP buys a CDMO
09 Oct 2023
Phase 2Clinical ResultPhase 3
BridgeBio shares longer-term PhII data in limb-girdle: BridgeBio said that patients with limb-girdle muscular dystrophy type 2I/R9 treated with BBP-418 saw “stabilization in NSAD scores and ambulatory measures” over 21 months in the 14-patient Phase II study. The company is already running a Phase III study that it hopes to use for an accelerated approval of the limb-girdle treatment, with glycosylated α-dystroglycan levels at 12 months as a surrogate endpoint. The confirmatory results from the study would be a clinical test for limb-girdle dystrophies called the North Star Assessment for Dysferlinopathy, or NSAD. — Lei Lei Wu
Preview
Source: EndPoints
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
SIGN UP
LOG IN
BECOME A PREMIUM SUBSCRIBER
For more details,please visit the original website
The content of the article does not represent any opinions of Synapse and its affiliated companies. If there is any copyright infringement or error, please contact us, and we will deal with it within 24 hours.
Organizations
Targets
Drugs
Hot reports
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Leverages most recent intelligence information, enabling fullest potential.